IL291137A - Methods and preparations for treating sickle cell disease with a profortin inhibitor (vit-2763) - Google Patents

Methods and preparations for treating sickle cell disease with a profortin inhibitor (vit-2763)

Info

Publication number
IL291137A
IL291137A IL291137A IL29113722A IL291137A IL 291137 A IL291137 A IL 291137A IL 291137 A IL291137 A IL 291137A IL 29113722 A IL29113722 A IL 29113722A IL 291137 A IL291137 A IL 291137A
Authority
IL
Israel
Prior art keywords
vit
compositions
methods
sickle cell
cell disease
Prior art date
Application number
IL291137A
Other languages
English (en)
Hebrew (he)
Original Assignee
Vifor Int Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vifor Int Ag filed Critical Vifor Int Ag
Publication of IL291137A publication Critical patent/IL291137A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
IL291137A 2019-10-22 2022-03-06 Methods and preparations for treating sickle cell disease with a profortin inhibitor (vit-2763) IL291137A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962924556P 2019-10-22 2019-10-22
EP19000483 2019-10-22
EP20163777 2020-03-17
EP20176336 2020-05-25
PCT/EP2020/079802 WO2021078889A1 (en) 2019-10-22 2020-10-22 Methods and compositions for treating sickle cell disease with a ferroportin inhibitor (vit-2763)

Publications (1)

Publication Number Publication Date
IL291137A true IL291137A (en) 2022-05-01

Family

ID=73005635

Family Applications (1)

Application Number Title Priority Date Filing Date
IL291137A IL291137A (en) 2019-10-22 2022-03-06 Methods and preparations for treating sickle cell disease with a profortin inhibitor (vit-2763)

Country Status (11)

Country Link
US (1) US20220274973A1 (cg-RX-API-DMAC7.html)
EP (1) EP4048262A1 (cg-RX-API-DMAC7.html)
JP (1) JP7594004B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220086563A (cg-RX-API-DMAC7.html)
CN (1) CN114765955B (cg-RX-API-DMAC7.html)
AU (1) AU2020369137A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022007616A2 (cg-RX-API-DMAC7.html)
CA (1) CA3154524A1 (cg-RX-API-DMAC7.html)
IL (1) IL291137A (cg-RX-API-DMAC7.html)
MX (1) MX2022004806A (cg-RX-API-DMAC7.html)
WO (1) WO2021078889A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4536683A4 (en) * 2022-06-07 2026-06-10 Protagonist Therapeutics Inc HEPCIDINE MIMETIC AGENTS FOR THE TREATMENT OF SICKLE CELL DISEASE
WO2024083980A1 (en) 2022-10-21 2024-04-25 Vifor (International) Ag Bicyclic ferroportin inhibitors
CN121511085A (zh) 2023-06-26 2026-02-10 威佛(国际)股份公司 用于遗传性血色素沉着病(hh)的治疗的膜铁转运蛋白抑制剂
WO2026041650A1 (en) 2024-08-20 2026-02-26 Vifor (International) Ag Ferroportin-inhibitors for the use in the treatment of lupus nephritis
WO2026120152A1 (en) 2024-12-06 2026-06-11 Vifor (International) Ag Prolonged-release dosage forms of ferroportin inhibitors for use in treating hereditary haemochromatosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017068089A2 (en) 2015-10-23 2017-04-27 Vifor (International) Ag Novel ferroportin inhibitors
US11191818B2 (en) * 2016-08-04 2021-12-07 Takeda Pharmaceutical Company Limited Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
ES2934492T3 (es) 2018-12-13 2023-02-22 Global Blood Therapeutics Inc Inhibidores de ferroportina y métodos de uso

Also Published As

Publication number Publication date
US20220274973A1 (en) 2022-09-01
AU2020369137A1 (en) 2022-04-07
BR112022007616A2 (pt) 2022-07-12
JP2023500060A (ja) 2023-01-04
KR20220086563A (ko) 2022-06-23
JP7594004B2 (ja) 2024-12-03
CN114765955A (zh) 2022-07-19
CA3154524A1 (en) 2021-04-21
EP4048262A1 (en) 2022-08-31
MX2022004806A (es) 2022-05-16
WO2021078889A1 (en) 2021-04-29
CN114765955B (zh) 2025-06-24

Similar Documents

Publication Publication Date Title
ZA202207394B (en) Compositions and methods for treating hemoglobinopathies
SI3999506T1 (sl) Zaviralci PARP1
SG11202103405TA (en) Compounds and compositions for treating conditions associated with nlrp activity
IL285886A (en) Preparations and methods for the treatment of laminopathy
IL288024A (en) Methods and preparations for the prevention of type 1 diabetes
IL281032A (en) PDE9 inhibitors for the treatment of sickle cell disease
IL289037A (en) Indanes as inhibitors of pd-l1
IL275767A (en) Compositions and methods for treating metabolic diseases
IL285796A (en) Methods and preparations for the treatment of cancer
ZA202205289B (en) Compositions and methods for treating liver disease
ZA202107235B (en) Compositions and methods for treating ocular disease
GB201903827D0 (en) New compounds and methods
IL287865A (en) Pde9 inhibitors for treating thalassemia
IL290325A (en) Biopharmaceutical preparations and related methods
IL287981A (en) Preparations and methods for the treatment of t-cell exhaustion
EP3768095A4 (en) Compositions and methods for treating diarrheal diseases
GB201903832D0 (en) New compounds and methods
ZA202107544B (en) Pde9 inhibitors for treating sickle cell disease
IL291336A (en) Methods and preparations for tissue regeneration
IL289586A (en) pi4kiii alpha micromolecule inhibiting preparation, method for its preparation and use
DK3821706T3 (en) Artificial roost for at least one chiropter, in particular for at least one bat and method for its construction
ZA202007183B (en) Compositions and methods for treating the eye
GB2601975B (en) Game court
IL290770A (en) Compounds and methods for treating oxalate-related diseases
IL288563A (en) Ethods and compositions for treating autoimmune diseases